Moderna’s mRESVIA (mRNA-1345) has become the first mRNA-based vaccine for respiratory syncytial virus (RSV) to receive FDA approval. The vaccine is indicated for the prevention of lower respiratory tract disease caused by RSV infection in adults aged 60 years and older. This milestone marks Moderna’s second FDA-approved product after its COVID-19 vaccine. Earlier this year,…